| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Dan Siskind, Nadia Friend, Anthony Russell, John J McGrath, Carmen Lim, Sue Patterson, Dylan Flaws, Terry Stedman, Vikas Moudgil, Savio Sardinha, Shuichi Suetani, Steve Kisely, Karl Winckel, Andrea Bake. CoMET: a protocol for a randomised controlled trial of co-commencement of METformin as an adjunctive treatment to attenuate weight gain and metabolic syndrome in patients with schizophrenia newly commenced on clozapine. BMJ open. vol 8. issue 3. 2018-09-06. PMID:29500217. |
comet: a protocol for a randomised controlled trial of co-commencement of metformin as an adjunctive treatment to attenuate weight gain and metabolic syndrome in patients with schizophrenia newly commenced on clozapine. |
2018-09-06 |
2023-08-13 |
Not clear |
| Feras Ali Mustaf. Use of Clozapine in Schizophrenia. JAMA psychiatry. vol 73. issue 10. 2018-08-03. PMID:27438537. |
use of clozapine in schizophrenia. |
2018-08-03 |
2023-08-13 |
Not clear |
| Joseph P McEvo. Use of Clozapine in Schizophrenia. JAMA psychiatry. vol 73. issue 10. 2018-08-03. PMID:27438689. |
use of clozapine in schizophrenia. |
2018-08-03 |
2023-08-13 |
Not clear |
| Michael Sawyer, Geraldine Goodison, Lesley Smith, Veta Peereboom, Kieran Dauber, Dan Siskin. Brugada pattern associated with clozapine initiation in a man with schizophrenia. Internal medicine journal. vol 47. issue 7. 2018-08-03. PMID:28677308. |
brugada pattern associated with clozapine initiation in a man with schizophrenia. |
2018-08-03 |
2023-08-13 |
Not clear |
| Amitkumar Chougule, Samir Kumar Praharaj, Shripathy M Bhat, P S V N Sharm. Prevalence and Factors Associated With Clozapine-Related Constipation: An Observational Study. Journal of clinical psychopharmacology. vol 38. issue 1. 2018-07-24. PMID:29257785. |
despite being a very effective treatment for resistant schizophrenia and bipolar disorder, use of clozapine is limited by adverse effects. |
2018-07-24 |
2023-08-13 |
human |
| Amir Krivoy, Roy Onn, Yael Vilner, Eldar Hochman, Shira Weizman, Amir Paz, Shmuel Hess, Roi Sagy, Shiri Kimhi-Nesher, Ehud Kalter, Tal Friedman, Zvi Friedman, Gil Bormant, Sharon Trommer, Avi Valevski, Abraham Weizma. Vitamin D Supplementation in Chronic Schizophrenia Patients Treated with Clozapine: A Randomized, Double-Blind, Placebo-controlled Clinical Trial. EBioMedicine. vol 26. 2018-07-20. PMID:29226809. |
vitamin d supplementation in chronic schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled clinical trial. |
2018-07-20 |
2023-08-13 |
Not clear |
| Robert L Smith, Tore Haslemo, Ole A Andreassen, Erik Eliasson, Marja-Liisa Dahl, Olav Spigset, Espen Molde. Correlation Between Serum Concentrations of N-Desmethylclozapine and Granulocyte Levels in Patients with Schizophrenia: A Retrospective Observational Study. CNS drugs. vol 31. issue 11. 2018-07-18. PMID:28948574. |
clozapine is restricted to use in patients with treatment-refractory schizophrenia due to the risk of a serious drop in absolute neutrophil granulocyte count (anc). |
2018-07-18 |
2023-08-13 |
Not clear |
| Veera M Rajagopal, Anto P Rajkumar, Kuruthukulangara S Jacob, Molly Jaco. Gene-gene interaction between DRD4 and COMT modulates clinical response to clozapine in treatment-resistant schizophrenia. Pharmacogenetics and genomics. vol 28. issue 1. 2018-07-13. PMID:29087970. |
gene-gene interaction between drd4 and comt modulates clinical response to clozapine in treatment-resistant schizophrenia. |
2018-07-13 |
2023-08-13 |
human |
| Veera M Rajagopal, Anto P Rajkumar, Kuruthukulangara S Jacob, Molly Jaco. Gene-gene interaction between DRD4 and COMT modulates clinical response to clozapine in treatment-resistant schizophrenia. Pharmacogenetics and genomics. vol 28. issue 1. 2018-07-13. PMID:29087970. |
clozapine is the drug of choice for treatment-resistant schizophrenia. |
2018-07-13 |
2023-08-13 |
human |
| Veera M Rajagopal, Anto P Rajkumar, Kuruthukulangara S Jacob, Molly Jaco. Gene-gene interaction between DRD4 and COMT modulates clinical response to clozapine in treatment-resistant schizophrenia. Pharmacogenetics and genomics. vol 28. issue 1. 2018-07-13. PMID:29087970. |
here, we studied independent and epistatic genetic associations of polymorphisms in drd4 (120-bp duplication) and comt (val158met) with clinical response to clozapine in people with treatment-resistant schizophrenia. |
2018-07-13 |
2023-08-13 |
human |
| Deanna L Kelly, Hadar Ben-Yoav, Gregory F Payne, Thomas E Winkler, Sheryl E Chocron, Eunkyoung Kim, Christopher Kitchen, Veronika Stock, Gopal Vyas, Raymond C Love, Heidi J Wehring, Kelli M Sullivan, Stephanie Feldman, Fang Liu, Robert P McMahon, Reza Ghodss. Blood Draw Barriers for Treatment with Clozapine and Development of a Point-of-Care Monitoring Device. Clinical schizophrenia & related psychoses. vol 12. issue 1. 2018-07-09. PMID:26218235. |
while clozapine (clz) is the most effective antipsychotic drug for schizophrenia treatment, it remains underused. |
2018-07-09 |
2023-08-13 |
Not clear |
| Julia E H Brown, Simone Denni. Actively Negotiating the Mind-Body Divide: How Clozapine-Treated Schizophrenia Patients Make Health for Themselves. Culture, medicine and psychiatry. vol 41. issue 3. 2018-07-09. PMID:28074346. |
for people with refractory schizophrenia on clozapine, the gold standard antipsychotic treatment in england and australia, the separation of mental and physical regimes of health is particularly pronounced, resulting in multiple, compartmentalised treatment registers. |
2018-07-09 |
2023-08-13 |
human |
| Felipe D Pacheco, Mauricio L DA Silva, Graziela Batista, Witória Santos, Adalberto A DE Castro, Lara Canever, Alexandra I Zugn. Olfactory deficit as a result of clozapine withdrawal syndrome in an animal model of schizophrenia: preliminary results. Anais da Academia Brasileira de Ciencias. vol 90. issue 2. 2018-07-06. PMID:29898114. |
olfactory deficit as a result of clozapine withdrawal syndrome in an animal model of schizophrenia: preliminary results. |
2018-07-06 |
2023-08-13 |
rat |
| Felipe D Pacheco, Mauricio L DA Silva, Graziela Batista, Witória Santos, Adalberto A DE Castro, Lara Canever, Alexandra I Zugn. Olfactory deficit as a result of clozapine withdrawal syndrome in an animal model of schizophrenia: preliminary results. Anais da Academia Brasileira de Ciencias. vol 90. issue 2. 2018-07-06. PMID:29898114. |
then, we tested clozapine withdrawal in association with two widely used schizophrenia models: neonatal immune challenge by polycitidilic-polyinosinic acid (polyi:c) and ketamine. |
2018-07-06 |
2023-08-13 |
rat |
| Felipe D Pacheco, Mauricio L DA Silva, Graziela Batista, Witória Santos, Adalberto A DE Castro, Lara Canever, Alexandra I Zugn. Olfactory deficit as a result of clozapine withdrawal syndrome in an animal model of schizophrenia: preliminary results. Anais da Academia Brasileira de Ciencias. vol 90. issue 2. 2018-07-06. PMID:29898114. |
it was produced, for the first time, an olfactory deficit induced by clozapine withdrawal in wistar rats subjected to schizophrenia animal models. |
2018-07-06 |
2023-08-13 |
rat |
| Seunghyun Jeon, Se Hyun Kim, Soon Young Shin, Young Han Le. Clozapine reduces Toll-like receptor 4/NF-κB-mediated inflammatory responses through inhibition of calcium/calmodulin-dependent Akt activation in microglia. Progress in neuro-psychopharmacology & biological psychiatry. vol 81. 2018-07-03. PMID:28431901. |
clozapine is an atypical antipsychotic agent used in the treatment of schizophrenia and severe mood disorders. |
2018-07-03 |
2023-08-13 |
Not clear |
| b' Dragana Ignjatovi\\xc4\\x87 Risti\\xc4\\x87, Dan Cohen, Andrea Obradovi\\xc4\\x87, Katarina Niki\\xc4\\x87-\\xc4\\x90uri\\xc4\\x8di\\xc4\\x87, Marija Dra\\xc5\\xa1kovi\\xc4\\x87, Darko Hini\\xc4\\x8. The Glasgow antipsychotic side-effects scale for clozapine in inpatients and outpatients with schizophrenia or schizoaffective disorder. Nordic journal of psychiatry. vol 72. issue 2. 2018-06-27. PMID:29125018.' |
the glasgow antipsychotic side-effects scale for clozapine in inpatients and outpatients with schizophrenia or schizoaffective disorder. |
2018-06-27 |
2023-08-13 |
Not clear |
| Dan Siskind, Victor Siskind, Steve Kisel. Clozapine Response Rates among People with Treatment-Resistant Schizophrenia: Data from a Systematic Review and Meta-Analysis. Canadian journal of psychiatry. Revue canadienne de psychiatrie. vol 62. issue 11. 2018-06-26. PMID:28655284. |
clozapine response rates among people with treatment-resistant schizophrenia: data from a systematic review and meta-analysis. |
2018-06-26 |
2023-08-13 |
Not clear |
| Dan Siskind, Victor Siskind, Steve Kisel. Clozapine Response Rates among People with Treatment-Resistant Schizophrenia: Data from a Systematic Review and Meta-Analysis. Canadian journal of psychiatry. Revue canadienne de psychiatrie. vol 62. issue 11. 2018-06-26. PMID:28655284. |
clozapine is the most effective antipsychotic for the 25% to 33% of people with schizophrenia who are treatment resistant, but not all people achieve response. |
2018-06-26 |
2023-08-13 |
Not clear |
| Dan Siskind, Victor Siskind, Steve Kisel. Clozapine Response Rates among People with Treatment-Resistant Schizophrenia: Data from a Systematic Review and Meta-Analysis. Canadian journal of psychiatry. Revue canadienne de psychiatrie. vol 62. issue 11. 2018-06-26. PMID:28655284. |
a 40% response rate to clozapine suggests that 12% to 20% of people with schizophrenia will be ultra-resistant. |
2018-06-26 |
2023-08-13 |
Not clear |